본문 바로가기
KERD
논문KCI 등재

2023 대한갑상선학회 무증상갑상선기능저하증 진료 권고안

2023 Korean Thyroid Association Management Guidelines for Patients with Subclinical Hypothyroidism

정재훈|김보현|안창호|박영주|이은경|김경진|김태용|정윤재|이종민|이가희|유원상|윤지희|김원배|구유정|강호철|강예은|박도준|정현경|정의달
대한갑상선학회 (Korean Thyroid Association)|2023.05|International Journal of Thyroidology|제16권 제1호|pp. 32-50|DOI 10.11106/ijt.2023.16.1.32

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

Management진단치료DiagnosisLevothyroxine갑상선자극호르몬Subclinical hypothyroidism무증상갑상선기능저하증Thyroid-stimulating hormone레보타이록신
주제분류의학일반

초록

Subclinical hypothyroidism (SCH), characterized by elevated serum thyroid-stimulating hormone (TSH) levels and normal free thyroxine levels, usually presents without symptoms, and is often discovered incidentally during routine blood test. The Task Force of the Korean Thyroid Association Committee of Clinical Practice Guidelines has established a guideline to evaluate and manage SCH; the guideline emphasizes the implementation of diagnostic criteria based on the TSH reference range for Koreans and focuses on the proven health benefits of levothyroxine (LT4) treatment. Based on the Korea National Health and Nutrition Examination Survey (2013-2015), serum TSH level of 6.8 mIU/L is considered the reference value for SCH. SCH can be categorized as mild (TSH 6.8-10.0 mIU/L) or severe (TSH ＞10.0 mIU/L), and patients are classified as adults (age ＜70 years) or elderly patients (age ≥70 years) depending on the health effects of LT4 treatment. An initial increase in serum TSH levels should be reassessed with a subsequent measurement, along with the thyroid peroxidase antibody test, preferably 2-3 months after the initial evaluation. Usually, LT4 treatment is not recommended for mild SCH in adults; however, treatment is necessary for severe SCH in patients with underlying coronary artery disease or heart failure and can be considered for coexisting dyslipidemia. LT4 treatment is not recommended for mild or even severe SCH in elderly patients, in general. Patients with SCH who receive LT4 treatment, the LT4 dosage should be personalized, and serum TSH levels should be monitored to ensure optimal LT4 dosage (dosage that is neither excessive nor insufficient). Patients with SCH who do not receive LT4 treatment require periodic follow-up at appropriate testing intervals determined by disease severity. The guideline also provides several educational points applicable in clinical settings.

Abstract

Subclinical hypothyroidism (SCH), characterized by elevated serum thyroid-stimulating hormone (TSH) levels and normal free thyroxine levels, usually presents without symptoms, and is often discovered incidentally during routine blood test. The Task Force of the Korean Thyroid Association Committee of Clinical Practice Guidelines has established a guideline to evaluate and manage SCH; the guideline emphasizes the implementation of diagnostic criteria based on the TSH reference range for Koreans and focuses on the proven health benefits of levothyroxine (LT4) treatment. Based on the Korea National Health and Nutrition Examination Survey (2013-2015), serum TSH level of 6.8 mIU/L is considered the reference value for SCH. SCH can be categorized as mild (TSH 6.8-10.0 mIU/L) or severe (TSH ＞10.0 mIU/L), and patients are classified as adults (age ＜70 years) or elderly patients (age ≥70 years) depending on the health effects of LT4 treatment. An initial increase in serum TSH levels should be reassessed with a subsequent measurement, along with the thyroid peroxidase antibody test, preferably 2-3 months after the initial evaluation. Usually, LT4 treatment is not recommended for mild SCH in adults; however, treatment is necessary for severe SCH in patients with underlying coronary artery disease or heart failure and can be considered for coexisting dyslipidemia. LT4 treatment is not recommended for mild or even severe SCH in elderly patients, in general. Patients with SCH who receive LT4 treatment, the LT4 dosage should be personalized, and serum TSH levels should be monitored to ensure optimal LT4 dosage (dosage that is neither excessive nor insufficient). Patients with SCH who do not receive LT4 treatment require periodic follow-up at appropriate testing intervals determined by disease severity. The guideline also provides several educational points applicable in clinical settings.

참고문헌 (119)

  1. Okosieme O, "Management of primary hypothyroidism : statement by the British Thyroid Association Executive Committee", Clin Endocrinol(Oxf), 84(6), pp.799~808 (2016)
  2. Garber JR, "Clinical practice guidelines for hypothyroidism in adults : cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association", Thyroid, 22(12), pp.1200~1235 (2012)
  3. Jonklaas J, "Guidelines for the treatment of hypothyroidism : prepared by the american thyroid association task force on thyroid hormone replacement", Thyroid, 24(12), pp.1670~1751 (2014)
  4. Pearce SH, "2013 ETA guideline : management of subclinical hypothyroidism", Eur Thyroid J, 2(4), pp.215~228 (2013)
  5. Guyatt G, "Grading strength of recommendations and quality of evidence in clinical guidelines : report from an american college of chest physicians task force", Chest, 129(1), pp.174~181 (2006)
  6. Canaris GJ, "The Colorado thyroid disease prevalence study", Arch Intern Med, 160(4), pp.526~534 (2000)
  7. Hollowell JG, "Serum TSH, T(4), and thyroid antibodies in the United States population(1988 to 1994) : national health and nutrition examination survey(NHANES III)", J Clin Endocrinol Metab, 87(2), pp.489~499 (2002)
  8. 장윤영, "건강한 한국인 성인의 혈청 갑상선호르몬 참고치", 예방의학회지, 41(2), pp.128~134 (2008), 대한예방의학회
  9. 김혜성, "Gestational Age-specific Cut-off Values Are Needed for Diagnosis of Subclinical Hypothyroidism in Early Pregnancy", Journal of Korean Medical Science, 30(9), pp.1308~1312 (2015), 대한의학회
  10. 김원구, "Thyroid Stimulating Hormone Reference Range and Prevalence of Thyroid Dysfunction in the Korean Population: Korea National Health and Nutrition Examination Survey 2013 to 2015", Endocrinology and Metabolism, 32(1), pp.106~114 (2017), 대한내분비학회
  11. Somwaru LL, "The natural history of subclinical hypothyroidism in the elderly : the cardiovascular health study", J Clin Endocrinol Metab, 97(6), pp.1962~1969 (2012)
  12. Jeon MJ, "Excessive iodine intake and thyrotropin reference interval : data from the Korean national health and nutrition examination survey", Thyroid, 27(7), pp.967~972 (2017)
  13. Park SY, "Age-and gender-specific reference intervals of TSH and free T4 in an iodine-replete area : data from Korean national health and nutrition examination survey IV(2013-2015)", PLoS One, 13(2), pp.e0190738~ (2018)
  14. 김미진, "Reference interval for thyrotropin in a ultrasonography screened Korean population", The Korean Journal of Internal Medicine, 30(3), pp.335~344 (2015), 대한내과학회[DOI]
  15. Moon S, "Relation of subclinical hypothyroidism is associated with cardiovascular events and all-cause mortality in adults with high cardiovascular risk", Am J Cardiol, 122(4), pp.571~577 (2018)
  16. Gurgel MHC, "Establishment of reference interval for thyroid-stimulating hormone using electrochemiluminescence assay in a healthy adult population from Fortaleza, Brazil", Arch Endocrinol Metab, 64(4), pp.362~368 (2020)
  17. Clerico A, "A multicenter study for the evaluation of the reference interval for TSH in Italy(ELAS TSH Italian Study)", Clin Chem Lab Med, 57(2), pp.259~267 (2018)
  18. Chen X, "Relationship of gender and age on thyroid hormone parameters in a large Chinese population", Arch Endocrinol Metab, 64(1), pp.52~58 (2020)
  19. Kwon H, "Age-specific reference interval of serum TSH levels is high in adolescence in an iodine excess area : Korea national health and nutrition examination survey data", Endocrine, 57(3), pp.445~454 (2017)
  20. Choi HS, "Prevalence of subclinical hypothyroidism in two population based-cohort : Ansung and KLoSHA cohort in Korea", Int J Thyroidol, 3(1), pp.32~40 (2010)
  21. van de Ven AC, "Thyrotropin versus age relation as an indicator of historical iodine intake", Thyroid, 25(6), pp.629~634 (2015)
  22. Loh TP, "Clinical interpretation of thyroid tests : considerations for reference intervals", Thyroid, 33(4), pp.404~406 (2023)
  23. Roelfsema F, "Thyrotropin secretion in mild and severe primary hypothyroidism is distinguished by amplified burst mass and basal secretion with increased spikiness and approximate entropy", J Clin Endocrinol Metab, 95(2), pp.928~934 (2010)
  24. Roelfsema F, "Thyrotropin secretion profiles are not different in men and women", J Clin Endocrinol Metab, 94(10), pp.3964~3967 (2009)
  25. Asvold BO, "Association of serum TSH with high body mass differs between smokers and never-smokers", J Clin Endocrinol Metab, 94(12), pp.5023~5027 (2009)
  26. Azim S, "Subclinical hypothyroidism : when to treat", Cleve Clin J Med, 86(2), pp.101~110 (2019)
  27. Livingston EH, "Subclinical hypothyroidism", JAMA, 322(2), pp.180~ (2019)
  28. Joung JY, "Effect of iodine restriction on thyroid function in subclinical hypothyroid patients in an iodine-replete area : a long period observation in a large-scale cohort", Thyroid, 24(9), pp.1361~1368 (2014)
  29. Biondi B, "Subclinical hypothyroidism : a review", JAMA, 322(2), pp.153~160 (2019)
  30. Kim TH, "Effect of seasonal changes on the transition between subclinical hypothyroid and euthyroid status", J Clin Endocrinol Metab, 98(8), pp.3420~3429 (2013)
  31. Teng W, "Effect of iodine intake on thyroid diseases in China", N Engl J Med, 354(26), pp.2783~2793 (2006)
  32. World Health Organization, "Urinary iodine concentrations for determining iodine status deficiency in populations" (2013), World Health Organization
  33. Caldwell KL, "Iodine status in pregnant women in the national children's study and in U. S. women(15-44 years), national health and nutrition examination survey 2005-2010", Thyroid, 23(8), pp.927~937 (2013)
  34. van de Ven AC, "Longitudinal trends in thyroid function in relation to iodine intake : ongoing changes of thyroid function despite adequate current iodine status", Eur J Endocrinol, 170(1), pp.49~54 (2014)
  35. Fatourechi V, "Effects of reducing the upper limit of normal TSH values", JAMA, 290(24), pp.3195~3196 (2003)
  36. Fatourechi V, "Subclinical hypothyroidism : an update for primary care physicians", Mayo Clin Proc, 84(1), pp.65~71 (2009)
  37. 유원상, "Subclinical Hypothyroidism: Prevalence, Health Impact, and Treatment Landscape", Endocrinology and Metabolism, 36(3), pp.500~513 (2021), 대한내분비학회[DOI]
  38. Cooper DS, "Subclinical thyroid disease", Lancet, 379(9821), pp.1142~1154 (2012)
  39. Presotto EM, "Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab : results of a large multicentre study", J Endocrinol Invest, 43(3), pp.337~345 (2020)
  40. Mammen JS, "Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C", Thyroid, 23(9), pp.1151~1158 (2013)
  41. Bianchi L, "Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma", Endocr Relat Cancer, 20(5), pp.R233~R245 (2013)
  42. 권오빈, "Effect of iodine restriction on short-term changes in thyroid function in patients with subclinical hypothyroidism", Journal of Nutrition and Health, 55(2), pp.250~262 (2022), 한국영양학회[DOI]
  43. Raza SA, "Subclinical hypothyroidism : controversies to consensus", Indian J Endocrinol Metab, 17(Suppl 3), pp.S636~42 (2013)
  44. Roberts L, "Stability of thyroid function in older adults : the Birmingham elderly thyroid study", Br J Gen Pract, 68(675), pp.e718~e726 (2018)
  45. 박우리, "Prospective Observation of 5-Year Clinical Course of Subclinical Hypothyroidism in Korean Population", Journal of Korean Medical Science, 28(11), pp.1622~1626 (2013), 대한의학회
  46. Delshad H, "The incidence of thyroid function abnormalities and natural course of subclinical thyroid disorders, Tehran, I. R. Iran", J Endocrinol Invest, 35(5), pp.516~521 (2012)
  47. Amouzegar A, "Natural course of euthyroidism and clues for early diagnosis of thyroid dysfunction : Tehran thyroid study", Thyroid, 27(5), pp.616~625 (2017)
  48. Li X, "Natural history of mild subclinical hypothyroidism in a middle-aged and elderly Chinese population : a prospective study", Endocr J, 64(4), pp.437~447 (2017)
  49. Diez JJ, "Spontaneous normalization of thyrotropin concentrations in patients with subclinical hypothyroidism", J Clin Endocrinol Metab, 90(7), pp.4124~4127 (2005)
  50. Bekkering GE, "Thyroid hormones treatment for subclinical hypothyroidism : a clinical practice guideline", BMJ, pp.l2006~ (2019)
  51. Ates I, "The effect of oxidative stress on the progression of Hashimoto's thyroiditis", Arch Physiol Biochem, 124(4), pp.351~356 (2018)
  52. Rosario PW, "Natural history of subclinical hypothyroidism with TSH <", =10 mIU, Clin Endocrinol(Oxf), pp.2016, 84(6)[DOI]
  53. 이정민, "Risk factors for hypothyroidism in euthyroid thyroid nodule patients with lymphocytic thyroiditis on fine needle aspiration cytology", The Korean Journal of Internal Medicine, 34(6), pp.1287~1296 (2019), 대한내과학회[DOI]
  54. Rotondi M, "Raised serum TSH in morbid-obese and non-obese patients : effect on the circulating lipid profile", Endocrine, 45(1), pp.92~97 (2014)
  55. Sang Z, "Long-term exposure to excessive iodine from water is associated with thyroid dysfunction in children", J Nutr, 143(12), pp.2038~2043 (2013)
  56. Monzani F, "Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism : a double blind, placebocontrolled study", J Clin Endocrinol Metab, 86(3), pp.1110~1115 (2001)
  57. Yazici M, "Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism : index of myocardial performance in the evaluation of left ventricular function", Int J Cardiol, 95(2-3), pp.135~143 (2004)
  58. Biondi B, "Mechanisms in endocrinology : heart failure and thyroid dysfunction", Eur J Endocrinol, 167(5), pp.609~618 (2012)
  59. Hak AE, "Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women : the Rotterdam study", Ann Intern Med, 132(4), pp.270~278 (2000)
  60. Monzani F, "Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism : a double-blind, placebo-controlled study", J Clin Endocrinol Metab, 89(5), pp.2099~2106 (2004)
  61. Taddei S, "Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism : beneficial effect of levothyroxine therapy", J Clin Endocrinol Metab, 88(8), pp.3731~3737 (2003)
  62. Shakoor SA, "Endothelial progenitor cells in subclinical hypothyroidism : the effect of thyroid hormone replacement therapy", J Clin Endocrinol Metab, 95(1), pp.319~322 (2010)
  63. Cabral MD, "Normal flow-mediated vasodilatation of the brachial artery and carotid artery intima-media thickness in subclinical hypothyroidism", Braz J Med Biol Res, 42(5), pp.426~432 (2009)
  64. Rodondi N, "Subclinical hypothyroidism and the risk of coronary heart disease and mortality", JAMA, 304(12), pp.1365~1374 (2010)
  65. Chaker L, "Subclinical hypothyroidism and the risk of stroke events and fatal stroke : an individual participant data analysis", J Clin Endocrinol Metab, 100(6), pp.2181~2191 (2015)
  66. Gencer B, "Subclinical thyroid dysfunction and the risk of heart failure events : an individual participant data analysis from 6 prospective cohorts", Circulation, 126(9), pp.1040~1049 (2012)
  67. Baumgartner C, "Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation", Circulation, 136(22), pp.2100~2116 (2017)
  68. Moon S, "Subclinical hypothyroidism and the risk of cardiovascular disease and all-cause mortality : a meta-analysis of prospective cohort studies", Thyroid, 28(9), pp.1101~1110 (2018)
  69. Stott DJ, "Thyroid hormone therapy for older adults with subclinical hypothyroidism", N Engl J Med, 376(26), pp.2534~2544 (2017)
  70. Mooijaart SP, "Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80years and older with subclinical hypothyroidism", JAMA, 322(20), pp.1977~1986 (2019)
  71. Razvi S, "Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality", Arch Intern Med, 172(10), pp.811~817 (2012)
  72. Andersen MN, "Levothyroxine substitution in patients with subclinical hypothyroidism and the risk of myocardial infarction and mortality", PLoS One, 10(6), pp.e0129793~ (2015)
  73. Peng CC, "Association of thyroid hormone therapy with mortality in subclinical hypothyroidism : a systematic review and meta-analysis", J Clin Endocrinol Metab, 106(1), pp.292~303 (2021)
  74. Inoue K, "Association of subclinical hypothyroidism and cardiovascular disease with mortality", JAMA Netw Open, 3(2), pp.e1920745~ (2020)
  75. de Moura Souza A, "Association between serum TSH concentration within the normal range and adiposity", Eur J Endocrinol, 165(1), pp.11~15 (2011)
  76. Kitahara CM, "Body fatness and markers of thyroid function among U. S. men and women", PLoS One, 7(4), pp.e34979~ (2012)
  77. Nyrnes A, "Serum TSH is positively associated with BMI", Int J Obes(Lond), 30(1), pp.100~105 (2006)
  78. Fox CS, "Relations of thyroid function to body weight : cross-sectional and longitudinal observations in a community-based sample", Arch Intern Med, 168(6), pp.587~592 (2008)
  79. Wolters B, "TSH and free triiodothyronine concentrations are associated with weight loss in a lifestyle intervention and weight regain afterwards in obese children", Eur J Endocrinol, 168(3), pp.323~329 (2013)
  80. Reinehr T, "Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids", J Clin Endocrinol Metab, 91(8), pp.3088~3091 (2006)
  81. Dall'Asta C, "Weight loss through gastric banding : effects on TSH and thyroid hormones in obese subjects with normal thyroid function", Obesity(Silver Spring), 18(4), pp.854~857 (2010)
  82. Chikunguwo S, "Influence of obesity and surgical weight loss on thyroid hormone levels", Surg Obes Relat Dis, 3(6), pp.631~635 (2007)
  83. Ding X, "The association between subclinical hypothyroidism and metabolic syndrome : an update meta-analysis of observational studies", Endocr J, 68(9), pp.1043~1056 (2021)
  84. Boekholdt SM, "Initial thyroid status and cardiovascular risk factors : the EPIC-Norfolk prospective population study", Clin Endocrinol(Oxf), 72(3), pp.404~410 (2010)
  85. Liu XL, "Alteration of lipid profile in subclinical hypothyroidism : a meta-analysis", Med Sci Monit, 20, pp.1432~1441 (2014)
  86. Meier C, "TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism : a double blind, placebo-controlled trial(Basel Thyroid Study)", J Clin Endocrinol Metab, 86(10), pp.4860~4866 (2001)
  87. Caraccio N, "Lipoprotein profile in subclinical hypothyroidism : response to levothyroxine replacement, a randomized placebo-controlled study", J Clin Endocrinol Metab, 87(4), pp.1533~1538 (2002)
  88. Teixeira PF, "Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled doubleblind clinical trial", Horm Metab Res, 40(1), pp.50~55 (2008)
  89. Li X, "The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism : a systematic review and meta-analysis of randomized controlled trials", Clin Endocrinol(Oxf), 87(1), pp.1~9 (2017)
  90. Abreu IM, "Subclinical hypothyroidism : to treat or not to treat, that is the question!A systematic review with meta-analysis on lipid profile", Endocr Connect, 6(3), pp.188~199 (2017)
  91. Bode H, "Association of hypothyroidism and clinical depression : a systematic review and meta-analysis", JAMA Psychiatry, 78(12), pp.1375~1383 (2021)
  92. Loh HH, "Association between subclinical hypothyroidism and depression : an updated systematic review and meta-analysis", BMC Psychiatry, 19(1), pp.12~ (2019)
  93. Zhao T, "Subclinical hypothyroidism and depression : a meta-analysis", Transl Psychiatry, 8(1), pp.239~ (2018)
  94. Feller M, "Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism : a systematic review and metaanalysis", JAMA, 320(13), pp.1349~1359 (2018)
  95. Parsaik AK, "Hypothyroidism and risk of mild cognitive impairment in elderly persons : a population-based study", JAMA Neurol, 71(2), pp.201~207 (2014)
  96. Rieben C, "Subclinical thyroid dysfunction and the risk of cognitive decline : a meta-analysis of prospective cohort studies", J Clin Endocrinol Metab, 101(12), pp.4945~4954 (2016)
  97. van Vliet NA, "Association of thyroid dysfunction with cognitive function : an individual participant data analysis", JAMA Intern Med, 181(11), pp.1440~1450 (2021)
  98. Pasqualetti G, "Subclinical hypothyroidism and cognitive impairment : systematic review and meta-analysis", J Clin Endocrinol Metab, 100(11), pp.4240~4248 (2015)
  99. Recker S, "Thyroid related quality of life in elderly with subclinical hypothyroidism and improvement on levothyroxine is distinct from that in young patients(TSAGE)", Horm Metab Res, 51(9), pp.568~574 (2019)
  100. Carlé A, "Does subclinical hypothyroidism add any symptoms? Evidence from a Danish population-based study", Am J Med, 134(9), pp.1115~1126e1 (2021)
  101. Razvi S, "The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism : randomized, crossover trial", J Clin Endocrinol Metab, 92(5), pp.1715~1723 (2007)
  102. Okosieme OE, "Adequacy of thyroid hormone replacement in a general population", QJM, 104(5), pp.395~401 (2011)
  103. Flynn RW, "Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy", J Clin Endocrinol Metab, 95(1), pp.186~193 (2010)
  104. Jorde R, "Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment", J Clin Endocrinol Metab, 91(1), pp.145~153 (2006)
  105. Parle J, "A randomized controlled trial of the effect of thyroxine replacement on cognitive function in communityliving elderly subjects with subclinical hypothyroidism : the Birmingham elderly thyroid study", J Clin Endocrinol Metab, 95(8), pp.3623~3632 (2010)
  106. Jaeschke R, "Does treatment with l-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism?", J Gen Intern Med, 11(12), pp.744~749 (1996)
  107. Burgos N, "Clinical outcomes after discontinuation of thyroid hormone replacement : a systematic review and meta-analysis", Thyroid, 31(5), pp.740~751 (2021)
  108. Radetti G, "Thyroid function in children and adolescents with Hashimoto's thyroiditis after l-thyroxine discontinuation", Endocr Connect, 6(4), pp.206~212 (2017)
  109. Livadas S, "Levothyroxine replacement therapy and overuse : a timely diagnostic approach", Thyroid (2018)
  110. Rosario PW, "Levothyroxine therapy in the subclinical hypothyroidism: a lifelong therapy? A long-term study", Clin Endocrinol (Oxf), 85(5), pp.819~820 (2016)
  111. Bach-Huynh TG, "Timing of levothyroxine administration affects serum thyrotropin concentration", J Clin Endocrinol Metab, 94(10), pp.3905~3912 (2009)
  112. Bolk N, "Effects of evening vs morning levothyroxine intake : a randomized double-blind crossover trial", Arch Intern Med, 170(22), pp.1996~2003 (2010)
  113. Benvenga S, "Altered intestinal absorption of L-thyroxine caused by coffee", Thyroid, 18(3), pp.293~301 (2008)
  114. Bell DS, "Use of soy protein supplement and resultant need for increased dose of levothyroxine", Endocr Pract, 7(3), pp.193~194 (2001)
  115. Liwanpo L, "Conditions and drugs interfering with thyroxine absorption", Best Pract Res Clin Endocrinol Metab, 23(6), pp.781~792 (2009)
  116. Gkotsina M, "Improved levothyroxine pharmacokinetics after bariatric surgery", Thyroid, 23(4), pp.414~419 (2013)
  117. Grozinsky-Glasberg S, "Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism : meta-analysis of randomized controlled trials", J Clin Endocrinol Metab, 91(7), pp.2592~2599 (2006)
  118. Kim JY, "Dietary iodine intake and urinary iodine excretion in normal Korean adults", Yonsei Med J, 39(4), pp.355~362 (1998)
  119. 이가희, "2023 대한갑상선학회 임신 중 및 산후 갑상선질환의 진단 및 치료 권고안 개정안", International Journal of Thyroidology, 16(1), pp.51~88 (2023), 대한갑상선학회[DOI]

관련 논문AI추천

무증상 갑상선기능저하증의 진단과 치료: 2023 대한갑상선학회 진료 권고안정현경대한내과학회 · 대한내과학회지2024 · 제99권 제3호불현성 갑상선기능저하증 노인 환자에서 Levothyroxine 치료 효과 분석금민정, 김경은, 김재송, 도민희, 손은선, 유윤미한국병원약사회 · 병원약사회지2022 · 제39권 제2호여덟 가지 시약으로 측정한 혈청 갑상선자극호르몬 결과값 차이: 무증상갑상선기능저하증 진료지침의 임상 적용을 위한 참고구간 비교 연구강호철, 김솔잎, 박영주, 송상훈, 유원상, 이경훈, 이은경, 이제훈, 이호영, 정윤재, 정현경, 팽진철, 한민제대한갑상선학회 · International Journal of Thyroidology2023 · 제16권 제2호노인에서의 갑상선기능 이상의 진단과 치료김진화대한갑상선학회 · International Journal of Thyroidology2012 · 제5권 제2호CORRIGENDUM: CORRECTION OF TEXT. 2023 대한갑상선학회 무증상갑상선기능저하증 진료 권고안강예은, 강호철, 구유정, 김경진, 김보현, 김원배, 김태용, 박도준, 박영주, 안창호, 유원상, 윤지희, 이가희, 이은경, 이종민, 정윤재, 정의달, 정재훈, 정현경대한갑상선학회 · International Journal of Thyroidology2023 · 제16권 제2호불현성 갑상선 기능저하증과 혈청 총 콜레스테롤, 저밀도 콜레스테롤 농도와의 상관성석성자, 유왕근대한예방한의학회 · 대한예방한의학회지2008 · 제12권 제1호

이 간행물의 다른 논문 (10건)

2023 대한갑상선학회 갑상선결절 진료 권고안주리히, 박영주, 박도준, 정찬권, 백승국, 김선욱, 이민경, 이은경, 이지예, 이상우, 이용상, 조윤영, 이영아, 나동규, 정윤재, 정유석, 이가희, 송영신, 오소원, 김원배, 강수환, 임동준, 강호철, 구본석pp. 1-312023 대한갑상선학회 임신 중 및 산후 갑상선질환의 진단 및 치료 권고안 개정안이가희, 정경연, 안화영, 임창훈, 박도준, 김선욱, 박영주, 이은경, 김진화, 박소영, 정윤재, 유원상, 강호철pp. 51-88Thyroid Cancer, Iodine, and Gene Mutation정재훈pp. 89-95회돌이 후두신경재생을 위한 신경도관의 활용김정미, 최정석pp. 96-100갑상선 질환의 방사성요오드 치료와 이차암 발생하정희, 홍채문, 이재태pp. 101-110
원문 보기